Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...
December 2024 seems to be the month of skepticism for Biogen Inc ( NASDAQ:BIIB ), as this biotechnology company focusing on neurological and neurodegenerative diseases has received multiple downgrades ...
It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that ...
BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap ...
BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...
Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal. Get ...
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a ...
Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...
Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...
Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback